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The availability of different treatment options for radically resectable gastric cancer reopened the question of treatment selection and
correct definition of high-risk categories. Lymphatic, blood vessel and perineural invasion (LBVI/PNI) seem to possess the necessary
potential to provide useful information for the clinical management of this disease. Seven hundred and thirty-four patients with
advanced gastric cancer who underwent curative gastrectomy were analysed according to the presence of LBVI/PNI. Patients were
divided into two groups: group A for patients with LBVI/PNI (189 patients 26%) and group B for patients without LBVI/PNI (545
patients, 74%). The disease-free survival (DFS) for patients in group A was 32.1 months, whereas it was not reached for patients in
group B (P¼0.0001); the median overall survival was 45.5 months for patients in group A, whereas it was not reached for patients in
group B (P¼0.0001). At multivariate analysis, the presence of LBVI/PNI appeared an independent prognostic factor for DFS and OS.
Our results were confirmed in subgroup analysis, separately considering stage I and early gastric cancer patients with and without
LBVI/PNI. Taken together, our findings suggest the importance of LBVI/PNI in gastric cancer as it may provide additional information
for identifying patients at high risk, who may be candidates for further medical treatment after or before surgery.
British Journal of Cancer (2006) 95, 445–449. doi:10.1038/sj.bjc.6603286 www.bjcancer.com
Published online 1 August 2006
& 2006 Cancer Research UK
Keywords: gastric cancer; lymphatic and vascular invasion; prognostic factors
                                                    
Although many advances have been made in the diagnosis and
treatment of gastric cancer, the global outcome for patients
diagnosed with this disease is still disappointing with a 5-year
survival rate not exceeding 30% of all cases in Western Countries
(Bouvier et al, 2002; Nitti et al, 2003).
In operable gastric cancer, the extent of surgery and the value of
adjuvant treatment remain matter of scientific debate, with surgery
still representing the cornerstone of any curative procedure
(Hohenberger and Gretschel, 2003; van de Velde and Peeters,
2003).
Although most clinical trials investigating adjuvant chemo-
therapy generated inconclusive results (Hermans et al, 1993; Earle
and Maroun, 1999, Cascinu et al, 2005), it has been reported that a
chemoradiotherapy adjuvant approach may improve the outcome
of radically resected gastric cancer by lowering the incidence of
local relapse (Macdonald et al, 2001).
More recently, the MAGIC trial by Cunningham et al (2005)
strongly suggested that perioperative chemotherapy could repre-
sent an interesting treatment option for patients with resectable
cancer of the stomach, but on the other hand only 43% of the
patients were able to complete postoperative treatment. However,
it is also important to point out that the value of any medical
treatment administered either pre- or postoperatively should be
considered according to the quality and extent of surgery, which
has been shown to significantly influence the outcome of gastric
cancer patients (Scartozzi et al, 2005, Smith et al, 2005).
The availability of various and different treatment options for
radically resectable gastric cancer patients has consequently
reopened the crucial question of both an accurate treatment
selection and a correct definition of high-risk categories, which
may help identifying subgroups of patients benefiting more from
additional medical treatments after (or before) radical surgery.
Together with classic variables well known to have a definite
prognostic value (i.e. T and N categories), many biological and
pathological factors have been indicated as possible prognostic
indicators, but often with conflicting results. Among the others,
lymphatic and blood vessel invasion (BVI) seemed to possess the
necessary potential to provide useful information for the clinical
management of patients with gastric cancer.
In fact, it has been suggested that venous infiltration could be a
valuable prognostic factor in gastric cancer involving muscolaris
and subserosal layer (Fotia et al, 2004) and lymphatic and BVI was
shown to be an independent risk factor for recurrence and poor
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sprognosis in patients with node-negative cancer of the stomach
(Hyung et al, 2002).
Moreover, in a prospective analysis among 459 patients
lymphatic vessel invasion (LVI) was found to independently
correlate with prognosis in patients with primary resected
adenocarcinoma of the oesophagogastric junction (Burkhard
et al, 2005).
Furthermore, some authors suggested that the presence of
neural invasion could have a negative prognostic impact on
prognosis of radically resected gastric cancer patients. (Tanaka
et al, 1997; Duraker et al, 2003).
Nevertheless, data about lymphatic, blood vessel (LBVI) in
early-stage and in lymph node-positive gastric cancer are lacking.
The objective of our study was to clarify the role of LBVI and
perineural invasion (PNI) as prognostic factor in a group of
patients who underwent surgical resection for gastric carcinoma,
with the aim to serve as a tool for a more accurate and rational
treatment selection.
PATIENTS AND METHODS
Patient selection
The patient’s study population was selected from a central
database, including 915 patients, affected by gastric cancer,
operated in four different Institutions.
Classification of the T, N and M factors was made according to
the numeric system introduced by the 5th TNM.
One hundred and eighty-one patients were excluded from our
analysis because of incomplete clinicopathologic data or not
radical surgery. As a result, 734 patients with advanced gastric
cancer who had undergone curative gastrectomy were analysed
according to the presence of LBVI/PNI.
We divided our patients into two groups: group A for patients
with LBVI/PNI and group B for patients without LBVI/PNI.
Follow-up of both groups occurred at 3-month intervals for 2
years, then at 6-month intervals for 3 years and yearly thereafter.
Follow-up consisted of physical examination, a complete blood
count, chest radiography and ultrasound of the abdomen or
computed tomography scanning as clinically indicated. The site
and date of first relapse and the date of death were recorded.
Data management and statistical analysis
Statistical analysis was performed with SAS software version 8.2.
for Windows (SAS Institute Inc., Cary, NC, USA). The association
between categorical variables was estimated by w
2 test. Survival
distribution was estimated by the Kaplan–Meier method (Kaplan
and Meier, 1958).
Significant differences in probability of relapsing between the
strata were evaluated by log-rank test.
Cox’s multiple regression analysis was used to assess the role of
LBVI/PNI as prognostic factor adjusted for those variables resulted
significant at univariate analysis.
Tested variables included sex (male vs female), age (o65 vs
X65years), grade of tumour differentiation (well and moderately
differentiated vs undifferentiated), depth of tumour infiltration
(pT1–2 vs pT3–4, pT1 vs pT2–4, pT1–3 vs pT4), absence or
presence of lymph node metastases (pN0 vs pNþ), type of
lymphadenectomy (extended vs limited, that is, 425 vs o25
removed lymph nodes), LVI (presence vs absence of lymphatic
invasion), BVI (presence vs absence of BVI), PNI (presence vs
absence of PNI) and LBVI/PNI (presence vs absence of LBVI/PNI).
Relative risk was defined as the ratio of the probability that an
event (recurrence or death) would occur to the probability that it
would not occur. The prognostic power of covariates was
expressed by calculation of a relative risk with a 95% confidence
interval (CI). A significant level of 0.05 was chosen to assess the
statistical significance.
For statistical analysis, overall survival (OS) and disease-free
survival (DFS) were defined, respectively, as the interval between
surgery to death or last follow-up visit and as the interval between
surgery to clinical progression or death or last follow-up visit if not
progressed.
RESULTS
Seven hundred and thirty-four patients were eligible for our
analysis: 441 males and 293 females with a median age at diagnosis
of 68years (range: 30–94years). Two hundred and thirty-seven
patients had stage I, 152 stage II, 188 stage IIIA, 98 stage IIIB and
59 stage IV.
Among 734 patients with advanced gastric cancer who had
undergone curative gastric resection, LBVI/PNI was present in 189
patients (group A, 26%), whereas it was absent in the remaining
545 patients (group B, 74%). Clinicopathological variables of both
groups are summarised in Table 1.
Only LVI was present in 73 patients (9.9%), only BVI was
present in 50 patients (6.8%) and only PNI was present in 16
patients (2.1%). Lymphatic vessel invasion and BVI (LBVI) were
present concurrently in 15 patients (2%), LVI and PNI were
present concurrently in 18 patients (2.5%) and BVI and PNI were
present concurrently in 17 patients (2.3%). At univariate analysis,
pT stage, pN stage, number of resected lymph nodes, LVI, BVI,
PNI and LBVI/PNI resulted prognostic factors for DFS and OS
(Table 2). In particular, the DFS for patients in group A was 32.13
months, whereas it was not reached for patients in group B
(P¼0.0001) (Figure 1). The presence of LBVI/PNI also resulted
determinant in OS with a median OS of 45.5 months for patients in
Table 1 Patients characteristics
Whole group Group A (%) Group B (%)
Number 734 189 (26) 545 (74)
Age (range) 68 (30–94) 69 (35–92) 67 (30–94)
Sex
Male 441 105 (55.6) 336 (61.7)
Female 293 84 (44.4) 209 (38.3)
Stage
I 237 32 (16.9) 205 (37.6)
II 152 40 (21.2) 112 (20.6)
IIIA 188 58 (30.7) 130 (23.8)
IIIB 98 35 (18.5) 63 (11.6)
IV 59 24 (12.7) 35 (6.4)
pT stage
pT1 175 21 (11.1) 154 (28.3)
pT2 150 39 (20.6) 111 (20.4)
pT3 374 115 (60.9) 259 (47.5)
pT4 35 14 (7.4) 21 (3.8)
pN stage
pN0 301 46 (24.3) 255 (46.8)
pN1 269 83 (43.9) 186 (34.1)
pN2 126 41 (21.7) 85 (15.6)
pN3 38 19 (10.1) 19 (3.5)
Istopathology
Diffuse 90 30 (15.8) 60 (11.0)
Intestinal 290 81 (42.9) 209 (38.4)
Signet cells 56 9 (4.8) 47 (8.6)
Diffuse+signet cells 66 17 (9.0) 49 (9.0)
Other 232 52 (27.5) 180 (33.0)
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(P¼0.0001) (Figure 2).
Groups A and B resulted statistically equivalent for all major
clinicopathologic characteristics. However, we found a significant
correlation between stage at diagnosis and presence or absence of
LBVI/PNI. In fact, LBVI/PNI was more often found in gastric
cancers in more advanced stages. Only 16.9% of gastric cancers
with LBVI/PNI were diagnosed in stage I vs 37.6% of gastric
cancers without LBVI/PNI (P¼0.0001). Moreover, only 6.4% of
gastric cancers without LBVI/PNI were diagnosed in stage IV vs
12.7% of gastric cancers with LBVI/PNI (P¼0.0095).
The LBVI/PNI status was found related to the presence or
absence of lymph nodes metastases: patients with LBVI/PNI more
frequently showed the presence of lymph nodes metastases in
comparison to patients without LBVI/PNI (P¼0.0001).
At multivariate analysis, the presence of LBVI/PNI appeared an
independent prognostic factor for DFS (hazards ratio (HR)¼0.62,
CI 0.48–0.80, P¼0.0002), which was also influenced by extension
within the gastric wall (HR¼0.38, CI 0.29–0.51, P¼0.0001), nodal
involvement (HR¼0.31, CI 0.22–0.43, P¼0.0001) and by the type
of lymphadenectomy (HR¼0.60, CI 0.44–0.82, P¼0.0012).
The presence of LBVI/PNI also resulted an independent
prognostic factor affecting OS, which was also influenced by
extension within the gastric wall, nodal involvement and by the
type of lymphadenectomy (Table 3).
Our results were confirmed in subgroups analysis, separately
considering stage I patients with and without LBVI/PNI. In fact,
among stage I patients with LBVI/PNI, OS was 82.67 months,
whereas it was not reached for those without invasion (P¼0.0001)
Table 2 Significant prognostic factors for OS at univariate analysis
Factor OS (months) Relative risk 95% CI P-value
pT stage
pT 1 NR 0.1339 0.2184–0.3970 0.0001
pT 2–4 68.2
pT1–2 NR 0.2773 0.2177–0.3826 o0.0001
pT3–4 55.1
pT1–3 NR 0.3201 0.06029–0.3019 o0.0001
pT4 34.5
pN stage
N0 158.5 0.2611 0.2259–0.3948 o0.0001
N+ 65.3
Resected lymph nodes
o25 58.8 1.535 1.023–2.117 0.0371
425 84.8
Lymphatic invasion
Yes 63.5 1.900 1.482–3.423 0.0001
No 148
Blood vessel invasion
Yes 35.9 3.179 3.914–11.60 o0.0001
No 142.1
Perineural invasion
Yes 33 3.178 3.830–13.62 o0.0001
No 150.8
LBVI/PNI
Yes 45.5 2.459 2.190–4.333 0.0001
No NR
CI, confidence interval; LBVI/PNI, lymphatic, blood vessel and perineural invasion; NR,
not reached; OS, overall survival.
0 12 24 36 48 60 72 84 96
0
25
50
75
100
DFS (months)
P
a
t
i
e
n
t
s
 
(
%
)
P= 0.0001
Figure 1 Disease-free survival of gastric cancer patients with LBVI/PNI
(——— group A) and without LBVI/PNI (-------- group B).
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Figure 2 Overall survival of gastric cancer patients with LBVI/PNI
(——— group A) and without LBVI/PNI (-------- group B).
Table 3 Significant prognostic factors for OS at multivariate analysis
Factor Relative risk 95% CI P-value
pT Stage
pT 1 0.3178 0.1638–0.6165 0.0007
pT 2–4
pT1–2 0.5550 0.3835–0.8032 0.0018
pT3–4
pT1–3 0.5327 0.3218–0.8819 0.0143
pT4
pN Stage
N0 0.4638 0.3256–0.6607 o0.0001
N+
Resected lymph nodes
o25 0.6766 0.4686–0.9769 0.0371
425
Lymphatic invasion
Yes 0.6846 0.4861–0.9641 0.0300
No
Blood vessel invasion
Yes 0.5216 0.3595–0.7567 0.0006
No
Perineural invasion
Yes 0.7093 0.4599–0.9393 0.0402
No
LBVI/PNI
Yes 0.52 0.39–0.69 0.0001
No
CI, confidence interval; LBVI/PNI, lymphatic, blood vessel and perineural invasion; OS,
overall survival.
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s(Figure 3). Also, DFS appeared influenced by the presence or
absence of LBVI/PNI in this latter group of patients as it was 73.03
months for patients with invasion, whereas it was not reached for
patients without invasion (P¼0.0003) (Figure 4).
Moreover, when we considered patients affected by early gastric
cancer (pT1 N0  or Nþ), we found similar results: patients with
LBVI/PNI experienced a median DFS and OS significantly worse
than patients without LBVI/PNI. Patients with LBVI/PNI had a
DFS of 59.37 months, whereas it was not reached for patients
without LBVI/PNI (P¼0.0002) (Figure 5). Median OS was not
reached neither for patients with LBVI/PNI nor for those without
LBVI/PNI, but the difference was statistically significant
(P¼0.0013) (Figure 6).
In order to evaluate the difference between LVI and BVI, as
prognostic factors in gastric cancer patients, we compared OS and
DFS of patients with LVI vs those of patients with BVI. We observed
that patients with BVI had a worse outcome in comparison with
patients with LVI: the OS of patients with LVI was 68.2 months,
whereas that of patients with BVI was 35.87 months (P¼0.012)
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Figure 3 Overall survival of stage I gastric cancer with LBVI/PNI (———
) and without LBVI/PNI (--------).
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Figure 4 Disease-free survival of stage I gastric cancer patients with
LBVI/PNI (———) and without LBVI/PNI (-------).
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Figure 5 Disease-free survival of early gastric cancer patients with LBVI/
PNI (———) and without LBVI/PNI (--------).
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Figure 6 Overall survival of early gastric cancer patients with LBVI/PNI
(———) and without LBVI/PNI (--------).
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Figure 7 Overall survival of gastric cancer patients with BVI (———) vs
gastric cancer patients with LVI (--------).
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Figure 8 Disease-free survival of gastric cancer patients with BVI
(———) vs gastric cancer patients with LVI (--------).
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s(Figure 7); DFS was 55.77 months for patients with LVI and 15.37
months for those with BVI (P¼0.012) (Figure 8).
DISCUSSION
Although most clinical trials investigating adjuvant chemotherapy
generated inconclusive results (Hermans et al, 1993; Earle and
Maroun, 1999; Cascinu et al, 2005), the trial by Cunningham et al
(2005) (the MAGIC trial) has re-opened the debate about
chemotherapy for operable gastric cancer patients. In this study,
503 patients affected by adenocarcinoma of the stomach,
oesophagogastric junction or lower oesophagus were randomised
to perioperative chemotherapy or surgery alone. The authors of
this study demonstrated that perioperative chemotherapy was able
to significantly improve progression-free survival and OS. How-
ever, in the chemotherapy arm only 43% of patients completed the
postoperative planned programme, probably as a consequence of
the fact that gastric cancer patients have been often shown to be
hardly compliant to postoperative chemotherapy (Cascinu et al
2005). On the other hand, it has also been previously reported that
a chemoradiotherapy adjuvant approach may improve the out-
come of radically resected gastric cancer by lowering the incidence
of local relapse (Macdonald et al, 2001).
The availability of various and different treatment options has
consequently reintroduced the crucial question of an accurate
treatment selection and a correct definition of high-risk categories,
which may help identifying subgroups of patients benefiting more
from additional medical treatments after (or before) radical
surgery.
Our findings suggest that the presence or absence of LBVI/PNI
is an important aspect influencing the clinical outcome of gastric
cancer patients, who underwent radical surgery and, more
interestingly, it appeared an independent prognostic factor
affecting DFS (P¼0.0002) and OS (P¼0.0001), which were also
influenced by variables already known to represent important
prognostic factors such as the extension within the gastric wall,
nodal involvement and the type of lymphadenectomy (Scartozzi
et al, 2005; Smith et al, 2005).
In the present analysis, we found a statistically significant
difference in stage at diagnosis, DFS and OS between patients with
LBVI/PNI and those without LBVI/PNI. In fact, the median DFS for
patients in group A was 32.1 months, whereas it was not reached
by patients in group B (P¼0.0001); the median OS was 45.5
months for patients in group A, whereas it was not reached for
patients in group B (P¼0.0001). At multivariate analysis, the
presence of LBVI/PNI appeared an independent prognostic factor
for DFS and OS. Our results were confirmed in subgroups analysis,
separately considering stage I and early gastric cancer patients
with and without LBVI/PNI.
Our observations seem to integrate well to what has been already
suggested by other studies hypothesising that LBVI/PNI may
represent a prognostic factor in oesophageal squamous cell cancer
and gastric cancer and that the prognostic value of these factors is
not influenced by tumour stage, grade of differentiation or lymph
node involvement (Gabbert et al, 1991; Kooby et al, 2003;
Burkhard et al, 2005).
Our data in early gastric cancer patients are of particular
relevance. Lymphatic, blood vessel and perineural invasion was, in
fact, able to identify subgroups of patients with extremely different
clinical outcome among cases usually considered at a low risk of
recurrence, thus offering an effective tool for treatment selection
and prognostic stratification in these cases.
Although prospective studies are needed, taken together our
findings underline the importance of a careful search for LBVI/PNI
in gastric cancer patients as it may provide additional useful
information for identifying patients who are at high risk and who
may be candidates for further medical treatment after or before
surgery.
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